Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical on Yttrium-90 for Treating Liver Cancer
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Incoming Orders
Berlin, 28 April 2021. Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have executed a long-term supply agreement for the use of EZAG's Yttrium-90 in Sirtex SIR-Spheres(R) Y-90 resin microspheres for liver cancer. The arrangement has an initial term of five years and guarantees Eckert & Ziegler a substantial share of Sirtex's rising global demand. It supplements the existing broad-based supply agreement that Sirtex and Eckert & Ziegler have been operating since 2009. The Eckert & Ziegler sales forecast for the 2021 financial year remains unaffected.
"This agreement cements our long-term relationship and makes it easier for both parties to plan accordingly. The order once again underlines our strong market position and competence as a leading production partner for the pharmaceutical industry", explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. "With our geographic expansion strategy, we offer our customers a reliable and worldwide supply of high-quality radioisotopes."
"With its global manufacturing network, Eckert & Ziegler is an ideal partner for us to supply yttrium-90 worldwide. Our therapy is used in more than 50 countries to treat liver cancer, and with our recently announced prospective, multi-center study for the treatment of hepatocellular carcinoma, we have the potential to expand our FDA-approved indication for the use of SIR-Spheres(R) in the U.S.," explains Kevin R. Smith, CEO of Sirtex Medical.
From its production facilities in Braunschweig, Germany, and Boston (MA), USA, Eckert & Ziegler supplies the Sirtex sites in Frankfurt, Boston and Singapore with yttrium-90.
About Eckert & Ziegler.
28.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Eckert & Ziegler Strahlen- und Medizintechnik AG|
|Phone:||+49 30 941084-138|
|Fax:||+49 30 941084-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1189939|
|End of News||DGAP News Service|